🇺🇸 FDA
Patent

US 9475839

Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

granted A61PA61P31/16A61P31/18

Quick answer

US patent 9475839 (Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P31/16, A61P31/18, A61P31/20, A61P35/00